Great post re "watch this space" re your reply to Shoonchin
However I am intrigued as to where the cash on hand figure of $3.03m (October ) came from. According to the Quarterly Cash Flow statement for Q/E 30th September 2013 cash on hand was around $1.76m.
According to Dr Collier (he mentioned the company's cash position during one of his interviews) the company has enough cash to last to the end of the INV102 (COPD) and INV103 (Lupus) trials so hopefully no Capital Raising in the short term will not be required.
So where to now???
i) Receipt of $1.46m re the R&D Rebate
ii) Favourable Court ruling against the ex CBIO directors
iii)Favourable results obtained from the Lupus & COPD Phase 11 trials
iv) Negotiations with a Multi International Pharma re INV103(lupus) with a $'000m upfront payment plus milestone payments, plus double digit royalties.
v) Part of the upfront payment of the Lupus Deal to fund the continued trials and in house commercialisation of INV002 and or INV004 utilising Dr Mitchell Glass’s expertise.
vi) Value of Invion Shares if i) to iv) are achieved – who knows???? - maybe double digit $$'s!!!!! – here’s hoping.
IVX Price at posting:
11.0¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)